Filing summary
Entity and period: The supplied filing is Athira Pharma, Inc.’s Form 10-K for the fiscal year ended December 31, 2022, not a Leonabio, Inc. filing. It reports annual results, not standalone 2022 Q4 results. Athira trades as ATHA on Nasdaq.
Business context and pipeline
Athira is a clinical-stage biotechnology company developing small molecules intended to enhance the HGF/MET system and treat neurodegenerative and nervous-system disorders. It has no approved products and has not generated product-sales revenue. Its lead candidate, subcutaneous fosgonimeton, is being studied in Alzheimer’s disease (AD) and Parkinson’s disease dementia/dementia with Lewy bodies; ATH-1020 is in Phase 1 development for neuropathic pain, and ATH-1105 remains in preclinical/IND-enabling work for ALS.
Financial results and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Research and development expense | $61.5 million | $42.8 million |
| General and administrative expense | $32.6 million | $21.2 million |
| Total operating expenses | $104.0 million | $64.0 million |
| Grant income | $5.2 million | $8.8 million |
| Other income, net | $3.2 million | $0.3 million |
| Net loss | $95.6 million | $54.9 million |
| Net loss per share, basic and diluted | $2.53 | $1.49 |
| Cash used in operating activities | $72.5 million | $43.1 million |
- At year-end, cash and cash equivalents were $96.0 million, short- and long-term investments were $149.2 million, and total cash, cash equivalents and investments were $245.2 million. Management estimated this would fund operations and capital needs for at least 12 months after the report date.
- Total assets were $258.2 million, total liabilities $23.0 million, and stockholders’ equity $235.1 million. The filing reports no debt balance; debt-related obligations are not identified as a material source of financing.
- There were no product sales. Operating or gross margins are therefore not meaningful. The net loss widened by $40.8 million year over year; operating expenses increased 47%, including a $10.0 million legal settlement accrual.
- Operating cash use increased by $29.4 million. Investing cash inflow of $57.7 million primarily reflected investment maturities; financing cash inflow was $0.7 million, versus $97.1 million in 2021, mainly from the prior-year follow-on offering.
Material developments, outlook and risks
- AD trial results: ACT-AD did not meet its primary or secondary endpoints in the protocol-specified analysis. Post hoc analyses in a pre-specified subgroup not taking background acetylcholinesterase inhibitors suggested directional benefits, but these findings do not establish efficacy.
- LIFT-AD: The trial was amended in September 2022 to focus on participants not taking background acetylcholinesterase inhibitors. An independent committee recommended continuing after an unblinded interim analysis. Athira targeted completion of enrollment by mid-2023 and topline results in early 2024; neither outcome is assured.
- Other milestones: SHAPE enrollment closed at 28 participants; topline data were expected in 2023. ATH-1020 completed the single-ascending-dose phase of Phase 1 with a reported favorable safety profile; further development remained under evaluation. ATH-1105 IND-enabling studies were targeted for completion in 2023, with a Phase 1 start planned for 2024.
- Funding: Athira expects continued losses and says substantial additional funding will be required. In January 2023 it established an at-the-market equity program for up to $75 million; no shares had been sold under it as of the filing. Future equity financing could dilute shareholders.
- Legal and scientific credibility: Athira recorded a $10.0 million expense and liability for a proposed settlement in a securities class action; the agreement in principle, reached in February 2023, remained subject to court approval. The company also disclosed a Department of Justice Civil Investigative Demand and an SEC subpoena, and a Washington State University review concerning image alterations in papers co-authored by its former CEO. Potential effects on reputation, licensed intellectual property, grants and operations remain uncertain. Other derivative litigation was stayed.
- Other risks: Clinical and regulatory outcomes are uncertain, development is costly, and the company relies on third-party research and manufacturing providers. Competition, patient enrollment, intellectual-property protection, reimbursement and access to capital could affect its prospects. The filing identifies the company as loss-making with no approved commercial product.
Key facts for investors to verify
- Confirm the issuer identity: the filing is for Athira Pharma, Inc. (ATHA), not Leonabio, Inc.
- Review final court approval and payment status of the proposed $10.0 million class-action settlement, and updates on the DOJ and SEC matters and WSU review.
- Check actual LIFT-AD enrollment, final trial results, and whether the amended study supports a clinically meaningful benefit in its targeted population.
- Monitor cash consumption, investment liquidity, and any ATM share sales or other financing; runway is management’s estimate based on its operating plan.
- Assess whether the licensed dihexa-related intellectual property and associated research-misconduct disclosures affect patent rights, grants, or development plans.